Bloodstream infection test wins FDA approval

The Food and Drug Administration approved a test Wednesday that can help physicians diagnose an infection and select the proper antibiotic much more rapidly than with existing tests.

The Verigene GP Blood Culture Nucleic Acid Test — which is known as the BC-GP test — can identify different types of Staphylococcus, including methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus, Enterococcus (including vancomycin-resistant Enterococci) and Listeria within hours of an infection starting, Medical News Today reports. Infectious diseases such as MRSA can devastate nursing homes.

Existing bacterial tests can take up to four days to culture, which can expose patients to higher risks and lessen the effectiveness of antibiotics. Treatment of an infection with the wrong antibiotic also can result in greater antibiotic resistance, experts warn. The new BC-GP test, made by Nanosphere, offers a leap forward in catching the disease early while evaluating antibiotic resistance, the company's CEO told Medical News Today.

More in News

Experts tell lawmakers: Obama Medicare proposals would hurt long-term care — or maybe not

Experts tell lawmakers: Obama Medicare proposals would hurt ...

U.S. lawmakers heard mixed messages at a hearing Tuesday on how proposed Medicare cost-sharing reforms would impact long-term care. The House Ways and Means Subcommittee on Health focused in particular ...

Nursing home administrators can rise to 'unrealistic expectations' with disaster management, expert ...

One day after a powerful tornado destroyed a hospital and devastated an Oklahoma town, long-term care stakeholders gathered at a disaster preparedness conference organized by the Center for Preparedness Education, a joint endeavor of the Creighton University School of Medicine and the University of Nebraska ...

Long-term care physicians respond to report on antipsychotic over-prescribing

The top professional association of long-term care physicians and medical directors has reiterated its commitment to reducing the use of antipsychotics for dementia care. It did so Tuesday, in response to a recent report that criticized prescribing practices.